Supplemental digital content 2. Common TEAEs (reported in ≥5% of patients) during the prospective ADT phase (pre-randomization)

|  |  |
| --- | --- |
| **Preferred terma** | **Prospective ADT (N=502); n (%)** |
| Patients with ≥1 TEAE | 379 (75.5) |
| Headache | 73 (14.5) |
| Nausea | 70 (13.9) |
| Insomnia | 60 (12.0) |
| Dry mouth | 53 (10.6) |
| Diarrhea | 36 (7.2) |
| Fatigue | 36 (7.2) |
| Constipation | 35 (7.0) |
| Dizziness | 31 (6.2) |
| Upper respiratory tract infection | 29 (5.8) |
| Hyperhidrosis | 25 (5.0) |

Six patients were enrolled twice in the study. Only data from the first enrollment phase are included.

aPatients are counted only once within each preferred term; n, number of patients, %, proportion of patients

TEAE, treatment-emergent adverse events